Protein trafficking encompasses the complex network of intracellular transport pathways that ensure proper protein synthesis, folding, modification, and delivery to their correct cellular compartments. In neurons, these pathways are especially critical because of the unique architecture: proteins synthesized in the cell body must be transported vast distances along axons and dendrites to reach synaptic terminals, while synaptic vesicle components must be recycled back for continued neurotransmission[@perier2012].
Disruption of protein trafficking pathways is increasingly recognized as a central mechanism in neurodegenerative disease pathogenesis. Unlike most other cell types, neurons are post-mitotic and extremely long-lived, placing extraordinary demands on their trafficking and clearance systems. When these systems falter, misfolded proteins accumulate, organelles become dysfunctional, and synaptic transmission breaks down — the hallmarks of neurodegeneration[@mendoza2019].
This page provides a comprehensive cross-disease synthesis of the major intracellular trafficking pathways and their dysfunction in Alzheimer's disease, Parkinson's disease, ALS, frontotemporal dementia, Huntington's disease, and related disorders.
The endoplasmic reticulum and Golgi apparatus form the primary biosynthetic hub for proteins destined for secretion, plasma membrane insertion, or lysosomal delivery. Nascent polypeptides enter the ER lumen where chaperones assist folding, and properly folded proteins proceed through the Golgi stack for post-translational modification and sorting[@steenhuis2019][@zhang2022].
Key machinery:
In neurodegeneration: AD shows prominent ER-Golgi fragmentation and COPII dysregulation. APP and its processing enzymes rely on this pathway — disruption leads to amyloidogenic APP processing[@zhang2022]. PD-associated mutations in GBA disrupt ER-Golgi trafficking of glucocerebrosidase. ALS-linked VAPB mutations impair ER-Golgi transport, causing ER stress[@huang2023]. Mutations in GAGBP2 disrupt ER-Golgi trafficking in FTD[@tsuji2019].
ER-Associated Degradation (ERAD): Misfolded proteins that cannot be refolded are retrotranslocated to the cytoplasm for proteasomal degradation. This pathway involves the SEL1L-HRD1 complex and is critical for neuronal protein quality control. ERAD dysfunction contributes to accumulation of misfolded proteins in AD, PD, and ALS[@liu2019].
The endosomal system serves as the major sorting platform for proteins entering from the plasma membrane (endocytosis) and from the biosynthetic pathway. Early endosomes mature through intermediate stages to late endosomes, which fuse with lysosomes for cargo degradation. The retromer complex redirects cargo from late endosomes back to the trans-Golgi network or plasma membrane, preventing lysosomal degradation of needed proteins[@mendoza2019].
Key machinery:
In neurodegeneration: VPS35 D620N mutation causes autosomal-dominant PD by disrupting retromer function. CHMP2B mutations cause familial ALS/FTD. Endosomal enlargement (Rab5 overexpression) is among the earliest changes in AD, driving BACE1 accumulation and amyloid production. In PD, LRRK2 G2019S hyperphosphorylates Rab effectors, disrupting endosomal trafficking[@vps35_2013][@mendoza2019].
See the Endosomal Trafficking Pathway and Endosomal Trafficking Disease Comparison pages for detailed mechanisms.
Neurons depend on rapid, tightly regulated synaptic vesicle trafficking for neurotransmitter release. Synaptic vesicles are loaded with neurotransmitter at the nerve terminal, translocate to active zones, fuse with the plasma membrane upon calcium influx, and are recycled through endocytosis for reuse. This cycle operates at millisecond timescales and requires exquisite molecular coordination[@sudpoth2004].
Key machinery:
In neurodegeneration: SNCA (alpha-synuclein) directly binds SNARE proteins and promotes SNARE complex assembly, but in disease states, aggregated alpha-synuclein impairs synaptic vesicle recycling, leading to neurotransmitter depletion and synaptic dysfunction[@bridi2022]. In AD, amyloid-beta oligomers bind presynaptic receptors and disrupt synaptic vesicle trafficking. ALS-linked TDP-43 aggregation disrupts synaptic vesicle protein mRNA transport. Huntington's disease mutant huntingtin impairs synaptic vesicle transport via Huntingtin-associated protein 1 (HAP1)[@roeper2023].
See the Synaptic Vesicle Trafficking and Synaptic Vesicle Trafficking Pathway pages for detailed mechanisms.
Autophagy is the cell's primary bulk degradation pathway, essential for clearing protein aggregates, damaged organelles, and intracellular pathogens. Three main types operate in neurons: macroautophagy (autophagosomes engulf cytoplasmic material), chaperone-mediated autophagy (direct translocation of KFERQ-motif proteins across the lysosomal membrane), and microautophagy (direct lysosomal invagination).
Key machinery:
In neurodegeneration: Autophagy-lysosomal dysfunction is a unifying feature across all major neurodegenerative diseases. Impaired autophagosome formation, failed axonal transport of autophagosomes, and lysosomal degradation deficits all contribute to protein aggregate accumulation[@zhang2017]. LRRK2 G2019S mutations hyperactivate mTOR, suppressing autophagy initiation. C9orf72 repeat expansions reduce autophagosome formation. TREM2 mutations impair microglial autophagy in AD.
See Autophagy-Lysosomal Pathway in AD, Autophagy-Lysosomal Pathway in PD, and Chaperone-Mediated Autophagy in Neurodegeneration for detailed pages.
Neurons face a unique transport challenge: the cell body must supply proteins, lipids, organelles, and signaling molecules to synaptic terminals located up to a meter away, while synaptic components must be recycled back. This is accomplished by microtubule-based motor proteins — kinesins for anterograde (cell body to synapse) and dynein for retrograde (synapse to cell body) transport[@kim2016].
Key machinery:
In neurodegeneration: Tau hyperphosphorylation disrupts kinesin binding to microtubules, causing cargo depletion in distal axons in AD[@chen2021]. LRRK2 mutations alter phosphorylation of kinesin light chain subunits, impairing axonal transport. ALS-causing DCTN1 mutations disrupt dynein-dynactin function, causing motor neuron degeneration. Mutant huntingtin sequesters HAP1, disrupting axonal transport of neurotrophic factors in HD[@kim2016].
See the Retrograde Axonal Transport Dysfunction and Selectivity of Neuronal Vulnerability pages for detailed mechanisms.
Mitochondria are dynamically transported to regions of high energy demand, particularly synaptic terminals and nodes of Ranvier. Damaged mitochondria are selectively eliminated via mitophagy, involving PINK1-PRKN/Parkin signaling in PD, and the Mitochondrial Rho (Miro)- Milton complex in neuronal transport.
Key machinery:
In neurodegeneration: PD-linked PINK1 and PRKN/Parkin mutations impair mitophagy, causing accumulation of damaged mitochondria. LRRK2 G2019S disrupts mitochondrial dynamics and transport. In ALS, SOD1 mutations cause mitochondrial fragmentation and transport deficits. See Mitochondrial Dysfunction in PD for detailed coverage.
| Trafficking Pathway | Alzheimer's Disease | Parkinson's Disease | ALS | Frontotemporal Dementia | Huntington's Disease |
|---|---|---|---|---|---|
| ER-Golgi Transport | COPII fragmentation; APP misprocessing[@zhang2022] | GBA trafficking blocks; ER stress[@huang2023] | VAPB mutations disrupt ER-Golgi[@falletta2022] | GRN mutations disrupt Golgi sorting | mHTT disrupts COPII assembly[@gomez2017] |
| Endosomal Pathway | Rab5 overexpression; BACE1 accumulation; early endosome enlargement | LRRK2 kinase ↑; Rab39B ↓; VPS35 dysfunction | CHMP2B endosomal block; TDP-43 impairs endosomal sorting | CHMP2B; VPS29 variants | Moderate endosomal changes |
| Retromer Function | SorLA loss; Sorl1 downregulation; APP trafficking altered | VPS35 D620N; SorLA/SORT1 involvement | Variable; TDP-43 affects retromer components | VPS29 rare variants; Sort1 involvement | Less prominent |
| Synaptic Vesicle Cycle | A-beta oligomers impair SNARE assembly; synapsin phosphorylation ↑ | Alpha-synuclein binds synaptobrevin; impairs vesicle recycling[@bridi2022] | TDP-43 disrupts synaptic vesicle protein transport; UNC13A variants | Less prominent; TDP-43 affects synaptic mRNAs | HAP1 impairs synaptic vesicle transport |
| Axonal Transport | Tau hyperphosphorylation disrupts kinesin; organelle depletion in distal axons[@chen2021] | LRRK2 phosphorylates kinesin light chains; mitochondrial transport ↓ | DCTN1 dynactin mutations; kinesin dysfunction; NMJ dieback[@kim2016] | Less prominent | mHTT sequesters HAP1; neurotrophic factor transport ↓ |
| Autophagy-Lysosomal | mTORC1 overactive; impaired autophagosome-lysosome fusion; cathepsin D ↓ | LRRK2 G2019S suppresses autophagy; GBA loss impairs lysosomal function | C9orf72 reduces autophagosome initiation; p62 aggregates | GRN haploinsufficiency impairs lysosomal function | mHTT impairs autophagosome formation |
| Mitochondrial Transport | Mild dysfunction; amyloid-beta damages mitochondria | PINK1/Parkin mitophagy defects; Miro1/2 involvement | SOD1 mitochondrial fragmentation; TDP-43 mitochondrial import ↓ | Less prominent | mHTT-Miro-Milton disruption |
Parkinson's Disease:
Alzheimer's Disease:
ALS/FTD:
Huntington's Disease:
Cross-disease trafficking regulators:
Trafficking dysfunction offers multiple therapeutic targets across diseases:
Small molecule approaches:
Gene therapy and ASO approaches:
See also: